CEOs, Senior Executives Highlight Strategies, M&A, and Expansions at DCAT Week

Chief executive officers and senior executives from DCAT member companies provided key updates on strategy, mergers and acquisitions, and expansions at the DCAT Member Company Announcement Forum held during DCAT Week in mid-March.

The executives highlighted key company activity impacting the pharmaceutical manufacturing value chain. SCHOTT, Catalent, Thermo Fisher Scientific, Cambrex, Lonza, BSP Pharmaceuticals, Servier CDMO, Selkirk Pharma, Seqens, Cerbios-Pharma, and ACG were among the companies taking the podium to provide their latest developments (see announcements below).

SCHOTT Plans $1-Billion Expansion in Pharma Packaging

Catalent Investing $214 Million to Expand Biologics Capabilities; Invests in Oral Delivery Capabilities

Thermo Fisher Scientific Investing $150 Million in Sterile Injectables Development and Manufacturing

Cambrex Updates Integration of Halo Pharma and Avista Pharma; Expands Small-Molecule API Mfg

Lonza Updates $100-Million Expansion for High-Potency APIs and Small-Molecule Mfg

BSP To Add High-Containment Capacity for Conjugation and Injectable Drug Products

Servier CDMO Invests $55 Million for Bioproduction and $7 Million for Industrial Prep Chromatography

New CDMO Selkirk Pharma Investing $30 Million in Aseptic Fill–Finish Facility

Seqens Investing $30 Million to Expand High-Potency Manufacturing

Cerbios-Pharma Investing in New High-Potency API Production Line and Conjugation Suite

ACG Expands Capsule Production in Brazil, India, and Croatia

Leave a Reply

Your email address will not be published. Required fields are marked *

Recent Feature Articles

What’s Trending Inside the CDMO/CMO Market?

What are key trends shaping the market for bio/pharmaceutical outsourcing? DCAT Value Chain Insights takes an inside look into the market drivers, trends, and key activity shaping the CDMO/CMO sector in small-molecules, biologics, and drug products.

US Bio/Pharma Market: Is Stronger Growth Ahead?

The US bio/pharma market showed positive signs in 2023, despite a decline in spending on COVID-19 vaccines and products. Overall, the US market grew by 2.3% last year, and by 9.9%, excluding COVID-19 products. What’s projected in the near term?

AI Front and Center for Supply Chain Management 

How will artificial intelligence (AI) shape sourcing and supply chain management? A newly released study by DCAT and a panel discussion at DCAT Week examined AI’s potential, the types of projects and activities for which AI may be applied, and its challenges to its use and adoption.

The CDMO/CMO Report: Injectable Drugs

Demand for fill–finish capacity and sterile manufacturing is high, led by bio/pharma companies’ product portfolios and development pipelines in biologics and other key products, such as GLP-1 drugs. A roundup of the latest expansions by CDMOs/CMOs.